Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regorafenib + trifluridine + tipiracil + Vaxart avian influenza vaccine
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
This entry refers to a combination of **regorafenib**, **TAS-102** (trifluridine/tipiracil), and **Vaxart's avian influenza vaccine** (ND1.1). Regorafenib is an oral multikinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor angiogenesis (VEGFR1-3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), and the tumor microenvironment (PDGFR, FGFR). TAS-102 is an oral cytotoxic chemotherapy consisting of trifluridine, a nucleoside analog that incorporates into DNA to cause strand breaks, and tipiracil, a thymidine phosphorylase inhibitor that prevents trifluridine degradation. The Vaxart avian influenza vaccine (ND1.1) is an oral recombinant adenoviral vector (Ad5) vaccine designed to deliver the H5 hemagglutinin antigen to the ileum to stimulate mucosal and systemic immunity. This specific combination of an oncology regimen and a prophylactic viral vaccine is not a recognized clinical entity and likely represents a concatenation of separate drug entries.
- Brand names
- StivargaLonsurf
- Other names
- regorafenib + TAS-102 + ND1.1regorafenib + trifluridine/tipiracil + Vaxart avian influenza vaccine
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)RAF1 (c-Raf-1 (Y340D/Y341D))TEK (Tie2)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)TYMP (Thymidine phosphorylase)RET (Rearranged during transfection receptor tyrosine kinase)HA (Hemagglutinin)
Beyond the preview
Go deeper on regorafenib + trifluridine + tipiracil + Vaxart avian influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regorafenib + trifluridine + tipiracil + Vaxart avian influenza vaccine.